EPIDYOLEX
Reason for request
First assessment.
Favourable opinion for reimbursement as adjunctive therapy of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older.
What therapeutic improvement?
Therapeutic improvement in the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2 years of age and older.
Role in the care pathway?
Seizures associated with Lennox-Gastaut syndrome
The management of seizures associated with Lennox-Gastaut syndrome is based on the rapid initiation of symptomatic anti-epileptic treatment in order to reduce their frequency and intensity, taking into consideration the context of significant drug resistance observed in this disease.
Sodium valproate is recommended as a first-line treatment. Lamotrigine is added to the treatment when sodium valproate monotherapy is not sufficiently effective, or is poorly tolerated. The other medicinal products with an MA in Lennox-Gastaut syndrome are as follows: topiramate, rufinamide, clonazepam, felbamate and clobazam, with different safety profiles.
A ketogenic diet and vagus nerve stimulation are salvage therapies in the event of failure of medicinal treatments in patients with Lennox-Gastaut syndrome. Corpus callosotomy-type palliative surgery is indicated as a last resort following the failure of drug therapy.
Role of EPIDYOLEX (cannabidiol) in the care pathway:
EPIDYOLEX (cannabidiol) is a treatment option as adjunctive therapy of seizures associated with Lennox-Gastaut syndrome (LGS) in conjunction with clobazam, for patients 2 years of age and older.
Seizures associated with Dravet syndrome
The management of seizures associated with Dravet syndrome is based on the rapid initiation of symptomatic anti-epileptic treatment in order to reduce the frequency and intensity of seizures, taking into consideration the context of significant drug resistance observed in this disease.
Sodium valproate in conjunction with benzodiazepines (clobazam or lorazepam) is recommended as a first-line treatment. The combination of valproate with topiramate may also be effective, but topiramate can only be used from 2 years of age.
Stiripentol (DIACOMIT) has an MA specifically in conjunction with sodium valproate and clobazam in the treatment of generalized tonic-clonic seizures in patients with Dravet syndrome whose seizures are not adequately controlled with the clobazam/sodium valproate combination.
A ketogenic diet and vagus nerve stimulation are salvage therapies in the event of failure of medicinal treatments in patients with Dravet syndrome.
Role of EPIDYOLEX (cannabidiol) in the care pathway:
EPIDYOLEX (cannabidiol) is a treatment option as adjunctive therapy of seizures associated with Dravet syndrome (DS) in conjunction with clobazam, for patients 2 years of age and older.
Special recommendations
The Committee warns that the multi-dose vial packaging with two dosing devices graduated in ml, whereas the dosage is expressed in mg, requires a conversion (from mg to ml), promoting the risk of medication errors and overdose. The Committee also highlights the importance of ensuring the dosage wording is clear on the medical prescription and providing adequate information to the persons responsible for dispensing and administering EPIDYOLEX (cannabidiol), including health professionals and the child’s family.
Clinical Benefit
Substantial |
The clinical benefit of EPIDYOLEX (cannabidiol) is substantial in the MA indications. |
Clinical Added Value
minor |
Considering:
the Committee deems that EPIDYOLEX (cannabidiol) provides a minor clinical added value (CAV IV) as adjunctive therapy of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older. |
-